OGN · Organon & Co.
$13.76
+0.00 (+0.00%)
At close · Aug 28
Going-concern doubt
— cleared Jul 31, 2026
The latest filing no longer states the doubt (first flagged May 4, 2026).
View the 10-Q filed Jul 31, 2026Market Cap
$3.61B
Shares
262.61M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$6.22B
-2.9%
FY2025
Net Income
$187M
-78.4%
FY2025
Gross Margin
53.3%
-4.7pp
FY2025
Diluted EPS
$0.72
-78.4%
FY2025
Operating Cash Flow
$700M
-25.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $6.13B | $6.22BG | $6.4BG | $6.26BG | $6.17BG | $6.3B | $6.53B | $7.78B | |
| $2.9B | $2.9B | $2.69B | $2.52B | $2.29B | $2.38B | $2.12B | $2.27B | |
| $3.23B | $3.31B | $3.72B | $3.75B | $3.88B | — | — | — | |
| — | 53.3% | 58.02% | 59.84% | 62.84% | — | — | — | |
| $358M | $366M | $469M | $528M | $471M | $443M | $210M | $220M | |
| $1.71B | $1.72B | $1.76B | $1.89B | $1.7B | $1.67B | $1.36B | $1.44B | |
| — | $205M | $145M | $116M | $116M | $103M | $86M | $284M | |
| $38M | $95M | $31M | $62M | $28M | $3M | $60M | $78M | |
| $468M | $504M | $520M | $527M | $422M | $258M | $0 | $0 | |
| $491M | $425M | $807M | $673M | $1.12B | $1.53B | $2.75B | $3.7B | |
| $282M | $238M | -$57M | -$350M | $205M | $178M | $496M | $390M | |
| $209M | $187M | $864M | $1.02B | $917M | $1.35B | $2.16B | $3.22B | |
| — | 3.01% | 13.49% | 16.33% | 14.85% | 21.43% | 33.07% | 41.38% | |
| $233M | $309M | $756M | $1.05B | $866M | $1.45B | $1.99B | $3.21B | |
| USD/shares | $0.79 | $0.72 | $3.36 | $4.01 | $3.61 | $5.33 | $8.52 | $12.69 |
| USD/shares | $0.78 | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 | $8.52 | $12.69 |
| shares | 262.61M | 259.5M | 257.05M | 255.24M | 254.08M | 253.54M | 253.52M | 253.52M |
| shares | — | 260.76M | 259.15M | 256.27M | 255.17M | 254.19M | 253.52M | 253.52M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: $1.11B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.80×
Peer median 5.12×
EV/EBIT
—
P/E (TTM)
17.64×
Peer median 26.88×
Peer medians compare against the 7 similar-size Drug Manufacturers - General companies (of 13 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Europe and Canada | $1,618,000,000 | $1,763,000,000 | $1,673,000,000 | $1,631,000,000 | $1,741,000,000 | $1,726,000,000 | $1,893,000,000 |
| United States | $1,604,000,000 | $1,572,000,000 | $1,478,000,000 | $1,437,000,000 | $1,383,000,000 | $1,408,000,000 | $2,021,000,000 |
| Latin America Middle East Russia and Africa | $1,072,000,000 | $1,034,000,000 | $965,000,000 | $895,000,000 | $841,000,000 | $857,000,000 | $923,000,000 |
| Asia Pacific and Japan | $1,000,000,000 | $1,050,000,000 | $1,129,000,000 | $1,143,000,000 | $1,173,000,000 | $1,535,000,000 | $1,789,000,000 |
| China | $829,000,000 | $847,000,000 | $864,000,000 | $917,000,000 | $933,000,000 | $873,000,000 | $1,027,000,000 |
| Other Countries | $93,000,000 | $137,000,000 | $154,000,000 | $151,000,000 | $233,000,000 | $133,000,000 | $124,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Nexplanon Implanon NXT | $921,000,000 | $963,000,000 | $830,000,000 | $834,000,000 | $769,000,000 | $680,000,000 | $787,000,000 |
| Zetia | $342,000,000 | $317,000,000 | $322,000,000 | $370,000,000 | $378,000,000 | $482,000,000 | $590,000,000 |
| Other Sundry Established Brands | $338,000,000 | $328,000,000 | $319,000,000 | $326,000,000 | $357,000,000 | $379,000,000 | $238,000,000 |
| Atozet | $324,000,000 | $473,000,000 | $519,000,000 | $457,000,000 | $458,000,000 | $453,000,000 | $391,000,000 |
| Other Non Opiod Pain Bone and Dermatology | $301,000,000 | $295,000,000 | $275,000,000 | — | $286,000,000 | $278,000,000 | $214,000,000 |
| Arcoxia | $265,000,000 | $270,000,000 | $257,000,000 | $241,000,000 | $244,000,000 | $258,000,000 | $288,000,000 |
| Follistim AQ | $264,000,000 | $237,000,000 | $262,000,000 | $229,000,000 | $237,000,000 | $193,000,000 | $241,000,000 |
| Nasonex | $262,000,000 | $276,000,000 | $266,000,000 | $260,000,000 | $206,000,000 | $218,000,000 | $293,000,000 |
| Singulair | $252,000,000 | $359,000,000 | $404,000,000 | $411,000,000 | $413,000,000 | $462,000,000 | $698,000,000 |
| Renflexis | $251,000,000 | $274,000,000 | $278,000,000 | $226,000,000 | $186,000,000 | $135,000,000 | $96,000,000 |
| Hadlima | $228,000,000 | $142,000,000 | $44,000,000 | $19,000,000 | $13,000,000 | $0 | — |
| Cozaar Hyzaar | $219,000,000 | $243,000,000 | $281,000,000 | $323,000,000 | $357,000,000 | $386,000,000 | $442,000,000 |
| Emgality Ravvow | $174,000,000 | $107,000,000 | $0 | — | — | — | — |
| Other Womens Health | $174,000,000 | $158,000,000 | $147,000,000 | $138,000,000 | $206,000,000 | $270,000,000 | $173,000,000 |
| Dulera | $153,000,000 | $203,000,000 | $194,000,000 | $180,000,000 | $190,000,000 | $222,000,000 | $217,000,000 |
| Diprospan | $150,000,000 | $139,000,000 | $91,000,000 | $122,000,000 | $125,000,000 | $118,000,000 | $102,000,000 |
| Fosamax | $143,000,000 | $151,000,000 | $159,000,000 | $152,000,000 | $175,000,000 | $180,000,000 | $197,000,000 |
| Vtama | $128,000,000 | $12,000,000 | $0 | $0 | — | — | — |
| Marvelon Mercilon | $127,000,000 | $134,000,000 | $134,000,000 | $110,000,000 | $98,000,000 | $95,000,000 | — |
| Other Cardiovascular | $126,000,000 | $133,000,000 | $139,000,000 | $146,000,000 | $191,000,000 | $239,000,000 | $134,000,000 |
| Clarinex | $123,000,000 | $127,000,000 | $136,000,000 | $125,000,000 | $111,000,000 | $130,000,000 | $142,000,000 |
| Propecia | $118,000,000 | $111,000,000 | $125,000,000 | $125,000,000 | $136,000,000 | $129,000,000 | $131,000,000 |
| Ganirelix Acetate Injection | $101,000,000 | $109,000,000 | $110,000,000 | $123,000,000 | $111,000,000 | — | — |
| Vytorin | $100,000,000 | $108,000,000 | $129,000,000 | $130,000,000 | $164,000,000 | $182,000,000 | $285,000,000 |
| Ontruzant | $99,000,000 | $141,000,000 | $155,000,000 | $122,000,000 | $126,000,000 | $115,000,000 | $83,000,000 |
| Proscar | $97,000,000 | $95,000,000 | $97,000,000 | $101,000,000 | $117,000,000 | $176,000,000 | $203,000,000 |
| Nuva Ring | $91,000,000 | $115,000,000 | $176,000,000 | $219,000,000 | $191,000,000 | $236,000,000 | $879,000,000 |
| Other Sundry Products | $82,000,000 | $115,000,000 | $121,000,000 | $146,000,000 | $200,000,000 | $107,000,000 | $102,000,000 |
| Brenzys | $80,000,000 | $77,000,000 | $73,000,000 | $75,000,000 | $63,000,000 | $74,000,000 | $72,000,000 |
| Jada | $74,000,000 | $61,000,000 | $43,000,000 | $20,000,000 | $3,000,000 | — | — |
| Other Respiratory | $52,000,000 | $53,000,000 | $64,000,000 | $61,000,000 | $89,000,000 | $118,000,000 | $25,000,000 |
| Other Biosimilars | $33,000,000 | $28,000,000 | $43,000,000 | — | — | — | $0 |
| Rosuzet | $24,000,000 | $49,000,000 | $70,000,000 | $71,000,000 | $68,000,000 | $130,000,000 | $120,000,000 |
| Asmanex | — | — | — | — | — | — | $94,000,000 |
| Aybintio | — | — | — | $39,000,000 | $36,000,000 | $6,000,000 | — |
| Cerazette | — | — | — | — | — | — | $71,000,000 |
| Diprosone | — | — | — | — | — | — | $84,000,000 |
| Emgality Rayvow | — | — | — | $0 | — | — | — |
| Orgalutron | — | — | — | — | — | $81,000,000 | $112,000,000 |
| Other Non Opioid Pain Bone And Dermatology | — | — | — | $273,000,000 | — | — | — |
| Remeron | — | — | — | — | — | — | $82,000,000 |
| Sinemet | — | — | — | — | — | — | $79,000,000 |
| Zocor | — | — | — | — | — | — | $112,000,000 |
Key facts
CIK
1821825
CUSIP
68622V106
13F (30d)
432 filings
413 filers
Visit website
Investor relations